CHANGES IN PLASMA EBV DNA IN NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY AT THAI NGUYEN NATIONAL HOSPITAL

Trần Bảo Ngọc; Trần Thị Kim Phượng; Vi Trần Doanh; Nguyễn Thị Hoa; Hoàng Kim Dung

doi:10.34238/tnu-jst.9588

CHANGES IN PLASMA EBV DNA IN NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY AT THAI NGUYEN NATIONAL HOSPITAL

About this article

Received: 13/01/24 Revised: 05/03/24 Published: 12/03/24

Authors

1. Tran Bao Ngoc , TNU – University of Medicine and Pharmacy
2. Tran Thi Kim Phuong, TNU – University of Medicine and Pharmacy
3. Vi Tran Doanh, TNU – University of Medicine and Pharmacy
4. Nguyen Thi Hoa, TNU – University of Medicine and Pharmacy
5. Hoang Kim Dung, TNU – University of Medicine and Pharmacy

Abstract

Epstein-Barr virus (EBV) is a major factor causing nasopharyngeal carcinoma and its load has many implications in screening, early detection as well as monitoring treatment response. The study aimed to determine the changes in plasma EBV DNA load level in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemoradiotherapy at Thai Nguyen National Hospital. A cross-sectional descriptive study was on 57 NPC patients which are measured for plasma EBV DNA load and treated with concurrent chemoradiotherapy from January 2022 to December 2023. The average age was 52.4; the male/female ratio was 2.2/1; 54.4% of patients were stage T3 or T4; 14.0% of patients had no lymph node metastasis; 63.2% of patients were stage III; the rate of EBV positive before treatment: 37.7% (0-8,960,000 copies/ml). Plasma EBV DNA was significantly increased in N0 patients and tend to be high in T3, T4 stage; stage III, IVA and elderly patients. After treatment, 95.3% of patients were EBV negative. High plasma EBV DNA load appeared to be associated with complete response to treatment. Thus, plasma EBV DNA load is related to both clinical characteristics and treatment outcomes of nasopharyngeal carcinoma.

Keywords

Load; Plasma EBV DNA; Nasopharyngeal carcinoma; Concurrent chemoradiotherapy; Thai Nguyen

Full Text:

PDF

References

[1] Y. Zhang, H. Rumgay, M. Li, S. Cao, and W. Chen, "Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling," JMIR Public Health Surveill, vol. 9, 2023, Art. no. e49968, doi: 10.2196/49968.

[2] C. T. H. Trinh, D. N. Tran, L. T. T. Nguyen, et al., "LMP1-EBV Gene Deletion Mutations and HLA Genotypes of Nasopharyngeal Cancer Patients in Vietnam," Pathophysiology, vol. 30, no. 1, pp. 1-12, 2023, doi: 10.3390/pathophysiology30010001.

[3] S. W. Tsao, C. M. Tsang, and K. W. Lo, "Epstein-Barr virus infection and nasopharyngeal carcinoma," Philos Trans R Soc Lond B Biol Sci., vol. 372, no. 1732, 2017, doi: 10.1098/rstb.2016.0270.

[4] L. D. Thuan, N. D. Kha, N. T. Minh, and L. Thuy, "Novel Patterns of the Epstein-Barr Nuclear Antigen (EBNA-1) V-Val Subtype in EBV-associated Nasopharyngeal Carcinoma from Vietnam," Balkan J Med Genet., vol. 22, no. 1, pp. 61-68, 2019, doi: 10.2478/bjmg-2019-0011.

[5] J. Yu, T. T. Pham, N. Wandrey, M. Daly, and S. D. Karam, "Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma," Cancers (Basel), vol. 13, no. 23, 2021, doi: 10.3390/cancers13236078.

[6] Y. Q. He, T. M. Wang, M. Ji, et al., "A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening," Nat Commun., vol. 13, no. 1, 2022, Art. no. 1966, doi: 10.1038/s41467-022-29570-4.

[7] R. Guo, Y. P. Mao, L. L. Tang, L. Chen, Y. Sun, and J. Ma, "The evolution of nasopharyngeal carcinoma staging," Br J Radiol., vol. 92, no. 1102, 2019, Art. no. 20190244, doi: 10.1259/bjr.20190244.

[8] L. Q. Ma, H. X. Wu, X. Q. Kong, et al., "Which evaluation criteria of the short-term efficacy can better reflect the long-term outcomes for patients with nasopharyngeal carcinoma?" Transl Oncol., vol. 20, 2022, Art. no. 101412, doi: 10.1016/j.tranon.2022.101412.

[9] Ministry of Health, Technical procedures for medical examination and treatment specialized in oncology, Decision No. 3338/QD-BYT dated September 9, 2013 (in Vietnammese), 2013.

[10] H. T. Pham, H. T. Tran, T. T. H. Nguyen, et al., "Changes in plasma EBV-DNA levels of nasopharyngeal cancer patients before and after treatment," Journal of Medical Research, vol. 3, no. 108, pp. 104-110, 2017.

[11] R. Feng, E. T. Chang, Z. Liu, et al., "Body mass index, body shape, and risk of nasopharyngeal carcinoma: A population-based case-control study in Southern China," Cancer Med., vol. 8, no. 4, pp. 1835-1844, 2019, doi: 10.1002/cam4.2027.

[12] N. C. Pham, T. X. Nguyen, N. T. Pham et al., "Pathological characteristics of nasopharyngeal carcinoma in Hue central hospital," Journal of Clinical Medicine, vol. 56, pp. 86-88, 2019.

[13] G. Andrei, E. Trompet, and R. Snoeck, "Novel Therapeutics for Epstein(-)Barr Virus," Molecules, vol. 24, no. 5, 2019, Art. no. 86, doi: 10.3390/molecules24050997.

[14] F. P. Zhao, X. Liu, X. M. Chen, et al., "Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma," Oncol Lett., vol. 10, no. 5, pp. 2888-2894, 2015, doi: 10.3892/ol.2015.3628.

[15] H. N. Vasudevan and S. S. Yom, "Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus," Hematol Oncol Clin North Am., vol. 35, no. 5, pp. 963-971, Oct. 2021, doi: 10.1016/j.hoc.2021.05.007.

DOI: https://doi.org/10.34238/tnu-jst.9588

Refbacks

There are currently no refbacks.



Remember me